Search Results
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
| Title | Publication Date | Price | Relevance |
|---|---|---|---|
| Winning Product Launch Strategies Maximizing sales from new pharmaceutical products |
Apr 2007 | £1,210 | 100% |
| Microscopes A World Market Review |
Nov 2009 | £1,895 | 98% |
| PharmaVitae Generics - Teva | Jul 2007 | £2,400 | 97% |
| Watson Pharmavitae Generics Profile |
Sep 2007 | £2,400 | 97% |
| 3D Medical Imaging A Worldwide Market Intelligence Report |
Nov 2009 | £1,895 | 96% |
| Probiotics A Global Update of Market Trends & Opportunities |
Nov 2009 | £1,895 | 96% |
| Allergy Drugs | Feb 2010 | £2,500 | 96% |
| Hand Sanitizers | Jun 2010 | £2,500 | 95% |
| Pharmaceutical Outsourcing Opportunities Post Launch Contract Manufacturing, and Sales and Marketing,2nd Edition |
Sep 2006 | £2,465 | 95% |
| Tampons | Feb 2011 | £2,845 | 95% |
| Hand Sanitizers US Market Trends |
Nov 2009 | £1,895 | 95% |
| Servier PharmaVitae Profile |
Feb 2007 | £3,605 | 95% |
| Novartis PharmaVitae Profile |
Jan 2007 | £3,605 | 94% |
| MedImmune PharmaVitae Profile |
Sep 2006 | £3,600 | 94% |
| Millennium: PharmaVitae Profile | Feb 2007 | £3,605 | 94% |
| Ear Protection Devices | Feb 2010 | £2,500 | 94% |
| Wockhardt Limited – Product Pipeline Review H2 2011 |
Nov 2011 | £315 | 94% |
| Biochips | Feb 2011 | £2,845 | 94% |
| Shire PharmaVitae Profile |
Oct 2006 | £3,600 | 94% |
| Ipsen PharmaVitae Profile |
Mar 2007 | £3,605 | 94% |
| Weight Control Products | Feb 2011 | £2,845 | 94% |
| Reformulation Strategies Comparisons of Past and Future Reformulation Strategies |
Sep 2006 | £4,805 | 94% |
| Holter Monitoring Systems | Feb 2011 | £2,845 | 94% |
| Carbondioxide Incubators A Global Market Perspective |
Nov 2009 | £1,895 | 94% |
| Deodorants | Feb 2011 | £2,655 | 93% |
| Merck Serono Biopharmaceuticals PharmaVitae Profile |
Jan 2007 | £3,605 | 93% |
| Analgesics in the BRIC (Brazil, Russia, India, China) Countries Market Overview and Forecasts to 2014 |
Jul 2010 | £1,260 | 93% |
| Cell-Based Assays | Apr 2011 | £2,655 | 93% |
| Antipsychotics Market to 2017 Patent Expiries for Zyprexa, Abilify, Seroquel and Geodon and the Launch of Generic Versions Will Limit Commercial Opportunities for Pipeline Molecules |
Jan 2012 | £2,215 | 93% |
| Serono PharmaVitae Profile |
Oct 2006 | £3,600 | 93% |
